Oncotarget

Reviews:

Regulation of p53: a collaboration between Mdm2 and Mdmx

Dongsheng Pei _, Yanping Zhang and Junnian Zheng

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:228-235. https://doi.org/10.18632/oncotarget.443

Metrics: PDF 5941 views  |   HTML 2887 views  |   ?  


Abstract

Dongsheng Pei1,2, Yanping Zhang1,2 and Junnian Zheng1

1 Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, China

2 Department of Radiation Oncology and Lineberger Comprehensive Cancer Center, School of Medicine, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Received: February 17, 2012; Accepted: March 2, 2012; Published: March 10, 2012;

Keywords: Mdm2, MdmX, p53, cancer

Correspondence:

Yanping Zhang,

Junnian Zheng,

Abstract

p53 plays an important role in the regulation of the cell cycle, DNA repair, and apoptosis and is an attractive cancer therapeutic target. Mdm2 and Mdmx are recognized as the main p53 negative regulators. Although it remains unclear why Mdm2 and Mdmx are both required for p53 degradation, a model has been proposed whereby these two proteins function independent of one another; Mdm2 acts as an E3 ubiquitin ligase that catalyzes the ubiquitination of p53 for degradation, whereas Mdmx inhibits p53 by binding to and masking the transcriptional activation domain of p53, without causing its degradation. However, Mdm2 and Mdmx have been shown to function collaboratively. In fact, recent studies have pointed to a more important role for an Mdm2/Mdmx co-regulatory mechanism of p53 regulation than previously thought. In this review, we summarize current progress in the field about the functional and physical interaction between Mdm2 and Mdmx, their individual and collaborative roles in controlling p53, and inhibitors that target Mdm2 and Mdmx as a novel class of anticancer therapeutics.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 443